About ProteinQure
ProteinQure is a clinical-stage biotech company focused on the design of novel exotic peptides with broad therapeutic applications, using its proprietary AI platform ProteinStudio™ to combine molecular simulations and machine learning for peptide-drug conjugate development. The company recently initiated the first clinical trial of a fully AI-designed peptide-drug conjugate (PQ203) in Canada and the United States, targeting triple-negative breast cancer. It serves pharmaceutical companies and research institutions, advancing precision medicine through tissue- and cell-specific drug delivery.
Company details
Funding
Total raised
$16M
Last stage
Series A
Investors
Founders
Christopher Ing
Co-founder and Chief Strategy Officer at ProteinQure, focused on computational protein drug discovery.
LinkedInLucas Siow
MBA from Rotman School of Management (U of T), MA in Economics from Penn, applied math background from UC Berkeley. Former data scientist and management consultant.
LinkedInTomas Babej
Co-founder and Chief Technology Officer at ProteinQure, focused on computational infrastructure for peptide drug design.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.